Literature DB >> 33437017

FMT for immunotherapy-refractory melanoma.

Jordan Hindson1.   

Abstract

Entities:  

Year:  2021        PMID： 33437017     DOI： 10.1038/s41575-021-00413-9

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.

Authors:  Gal Markel; Ben Boursi; Erez N Baruch; Ilan Youngster; Guy Ben-Betzalel; Rona Ortenberg; Adi Lahat; Lior Katz; Katerina Adler; Daniela Dick-Necula; Stephen Raskin; Naamah Bloch; Daniil Rotin; Liat Anafi; Camila Avivi; Jenny Melnichenko; Yael Steinberg-Silman; Ronac Mamtani; Hagit Harati; Nethanel Asher; Ronnie Shapira-Frommer; Tal Brosh-Nissimov; Yael Eshet; Shira Ben-Simon; Oren Ziv; Md Abdul Wadud Khan; Moran Amit; Nadim J Ajami; Iris Barshack; Jacob Schachter; Jennifer A Wargo; Omry Koren
Journal:  Science       Date:  2020-12-10       Impact factor: 47.728
  1 in total
  2 in total

1.  Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.

Authors:  Fangfang Xu; Tingwei Liu; Zhuonan Zhou; Chang Zou; Shaohua Xu
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

Review 2.  Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment.

Authors:  Hui Xu; Chenxi Cao; Yuqing Ren; Siyuan Weng; Long Liu; Chunguang Guo; Libo Wang; Xinwei Han; Jianzhuang Ren; Zaoqu Liu
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.